In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.


The free consultation period for this content is over.

It is now only available year-round to EHRA Ivory (& above) Members, Fellows of the ESC and Young combined Members

Phrenic nerve injury during pulmonary vein isolation using the second-generation cryoballoon: first results of the worldwide YETI registry

Session Best graded abstracts

Speaker Christian-Hendrik Heeger

Congress : EHRA 2019

  • Topic : arrhythmias and device therapy
  • Sub-topic : Rhythm Control, Catheter Ablation
  • Session type : Abstract Session
  • FP Number : 846

Authors : CH Heeger (Luebeck,DE), A Pott (Ulm,DE), A Rillig (Hamburg,DE), A Metzner (Hamburg,DE), S Cay (Ankara,TR), N Grosse (Luebeck,DE), S Miyazaki (Tsuchiura, Ibaraki,JP), A Arash (Sacramento,US), JR Ehrlich (Wiesbaden,DE), H Wirth (Ulm,DE), V Tscholl (Berlin,DE), KH Kuck (Hamburg,DE), T Dahme (Ulm,DE), RR Tilz (Luebeck,DE)

15 views

Authors:
CH Heeger1 , A Pott2 , A Rillig3 , A Metzner3 , S Cay4 , N Grosse1 , S Miyazaki5 , A Arash6 , JR Ehrlich7 , H Wirth2 , V Tscholl8 , KH Kuck3 , T Dahme2 , RR Tilz1 , 1University of Luebeck, Medical clinic II - Luebeck - Germany , 2Cardiology - Ulm - Germany , 3Asklepios Clinic St. Georg, Department of Cardiology - Hamburg - Germany , 4Yuksek Ihtisas Heart-Education and Research Hospital - Ankara - Turkey , 5Tsuchiura Kyodo Hospital - Tsuchiura, Ibaraki - Japan , 6Mercy Heart Institute - Sacramento - United States of America , 7St. Josefs-Hospital , Cardiology - Wiesbaden - Germany , 8Charite - Campus Benjamin Franklin, Cardiology - Berlin - Germany ,

Citation:

Background: Second-generation cryoballoon (CB2) based pulmonary vein isolation (PVI) has emerged as a safe and effective treatment option for symptomatic atrial fibrillation (AF). Although published complication rates of CB2 based-PVI are relatively low and several safety algorithms have been implemented in the protocols the most frequent complication is right-sided phrenic nerve injury (PNI). The reported incidence of PNI varies from 2-5% of patients. However data on PNI characteristics as well as follow-up is sparse.

Purpose: We aimed to evaluate the incidence, characteristics and outcome of PNI during after CB2 based-PVI in a large patients population.

 Methods: From July 2012 to August 2018 a total of 5371 patients received CB2 based-PVI in nine EP centers (Germany: 6, Turkey: 1, Japan: 1, USA: 1).
Resuls: A total of 209 (3.9%) of patients experienced PNI during treatment of the right superior (82%) or inferior (18%) pulmonary vein. The mean time to PNI was 124±48 seconds and the mean temperature at the time of PNI was -48.7±8 °C. The applications were interrupted using double-stop technique in 189/209 (90%). In 146/209 (70%) a CMAP was utilized. At the end of the procedure  PNI persistent in 42.6% of patients. Fluoroscopic or sonographic evaluation of PNI was performed 1-3 days after the procedure and revealed persistent PNI in 28.2% of patients. Dyspnea before discharge was reported in 10% of patients with persistent PNI. Patients follow up at 1-3, and 6-12 months included fluoroscopy and a visit in an outpatient clinic. After 1-3 months 12% of patients showed persistent PNI including 6.7% of patients complaining of dyspnea. After 6-12 months of follow-up including fluoroscopic evaluation PNI was persistent in 3.3% of patients while dyspnea was reported by 1.4% patients. Overall permanent PNI after 6-12 months was evaluated in 0.13% of patients. Only 0.06% of the overall population of 5371 patients showed permanent and symptomatic PNI.
Clonclusion: The incidence of PNI during CB2-based PVI is low. About 57.4% of PNI recovered until the end of the procedure. Most of PNI resulting from CB2-based PVI recovered after 12 months. Symptomatic permanent PNI is very rare in patients after CB2-based PVI.

The free consultation period for this content is over.

It is now only available year-round to EHRA Ivory (& above) Members, Fellows of the ESC and Young combined Members



Based on your interests

Three reasons why you should become a member

Become a member now
  • 1Access your congress resources all year-round on the New ESC 365
  • 2Get a discount on your next congress registration
  • 3Continue your professional development with free access to educational tools
Become a member now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim, Bristol-Myers Squibb and Pfizer Alliance, and Novartis Pharma AG. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are